+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care



A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care



European Journal of Cancer 36(Suppl 1): S15-S21



Studies of primary prophylaxis of febrile neutropenia with recombinant granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim), administered to all patients starting with the initial course of chemotherapy, have demonstrated an economic advantage over a wide range of settings. In these analyses, the threshold risk for febrile neutropenia at which a cost saving is realised is inversely related to the direct medical costs of hospitalisation. Clinical practice guidelines for the use of filgrastim have been developed based on these observations. Recent studies incorporating indirect institutional costs have demonstrated that cost savings can be achieved at substantially lower febrile neutropenia risk thresholds than previously estimated. Despite the demonstrated efficacy of filgrastim in primary prophylaxis, its value may be further enhanced through the appropriate selection of patients for such therapy and a better understanding of the importance of sustaining dose intensity in specific malignancies. Clinical prediction models capable of identifying individuals at high risk for neutropenic complications yield further reductions in febrile neutropenia risk thresholds and treatment costs in patients receiving cancer chemotherapy. Prediction models can also be used to evaluate the cost-effectiveness or cost-efficiency of filgrastim use. Such as model has recently been developed and validated and is described here which incorporates both baseline clinical characteristics as well as the results of the first cycle of chemotherapy in patients with early-stage breast cancer. A cost-effectiveness ratio of USdollar sign 34297 (Euro 32 002) per year of life saved (YLS) was calculated based on dose-response assumptions derived from a previously reported adjuvant breast cancer trial studying the impact of dose reduction on disease-free survival. This figure is comparable with accepted cost-effectiveness ratios for other interventions, e.g. USdollar sign 45 000/LYS (Euro 41 989) for renal dialysis for patients with end-stage renal disease. The cost-effectiveness of filgrastim was evident over a wide range of clinical and cost assumptions. Clinical prediction models permit rational and cost-effective selection of patients for filgrastim support. Current guidelines should be re-evaluated in light of new information available on both the total cost of febrile neutropenia, as well as the cost-effectiveness of these agents in specific clinical situations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010081038

Download citation: RISBibTeXText

PMID: 10785605

DOI: 10.1016/s0959-8049(99)00257-9


Related references

Visual aid tool to improve decision making in acute stroke care. International Journal of Stroke 11(8): 868-873, 2016

Decentralization of decision-making to improve patient care. Hospital Administration in Canada 18(3): 34 36-7, 1976

Web-based outcomes measurement tools complement managed-care decision making and improve patient care. Ons News 14(2): 8, 1999

The Goals of Patient Care project: implementing a proactive approach to patient-centred decision-making. Internal Medicine Journal 44(10): 961-966, 2014

Patient involvement in decision making in primary care clinics: development of a measuring tool. Atencion Primaria 42(5): 257-263, 2010

Extending the P4P agenda, part 1: how Medicare can improve patient decision making and reduce unnecessary care. Health Affairs 26(6): 1564-1574, 2007

Will shared decision making between patients with chronic musculoskeletal pain and physiotherapists, osteopaths and chiropractors improve patient care?. Family Practice 29(2): 203-212, 2012

President's page: employing shared decision-making models to improve care and patient value: a cardiovascular professional initiative. Journal of the American College of Cardiology 56(24): 2046-2048, 2011

Trends influencing the cost of care and patient safety. Decision-making in five key areas can improve clinical and economic performance. Health Management Technology 27(7): 18 20, 2006

Patient care. Making time to improve on care. Health Service Journal 117(6086): 28-29, 2007

A planned care approach and patient registry to improve adherence to clinical guidelines for the diagnosis and management of attention-deficit/hyperactivity disorder. Academic Pediatrics 15(3): 289-296, 2016

A pilot randomized controlled trial of a decision support tool to improve the quality of communication and decision-making in individuals with atrial fibrillation. Journal of the American Geriatrics Society 60(8): 1434-1441, 2012

New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer. Southern Medical Journal 91(2): 196-201, 1998

Exploring real-time patient decision-making for acute care: a pilot study. Western Journal of Emergency Medicine 15(6): 675-681, 2014